Introduction & Objective: Chronic kidney disease, or CKD, impacts approximately one in three of these diabetic patients. An estimated 37 million people in the US have CKD and 90% are unaware due to the lack of associated symptomatology. Routine monitoring of CKD-related biomarkers such as eGFR (estimated glomerular filtration rate) and UACR (urine albumin-creatinine ratio) help aid in early diagnosis, and can prevent progression into later stages where hemodialysis or transplants are needed. Advances in home-collected laboratory tests have now made it easier to perform this needed screening.
Methods: A retrospective analysis of eGFR and UACR home-collected, laboratory test results from January 1, 2020 through January 31, 2024 as part of Kidney Health program directed at diabetic individuals at high risk for CKD was conducted.
Results: Of 902,802 results available, 8.44% of eGFR (n = 73,788/873,617) results and 10.94% (n = 3,194/29,185) of UACR results were categorized as abnormal or critical. All patients with critical values received outreach and instructions on how to seek follow-up care.
Conclusions: Critical UACR results were 3.6x more frequent than those for eGFR, highlighting the need for both tests to assess kidney health. Patients who receive abnormal or critical result values received outreach and were directed to follow up with in-person healthcare providers to receive treatment and/or lifestyle interventions to slow progression of CKD. At-home lab testing combined with counseling is effective for closing healthcare gaps in a diabetic population.
M.J. Spicer: Employee; Everly Health. J. Miller: None. G. Westfield: Employee; Everly Health. L. Northrop: None. G. Gaviola: None.
